If adopted, S. 64 would prohibit brand name drug companies from compensating generic or biosimilar drug companies to delay the entry of generic or biosimilar drugs into the market.
Senator Amy Klobuchar (MN) introduced S. 64 on January 9, 2019. It has since been referred to the Committee on the Judiciary.
For more information or to view a list of cosponsors, click here.
